On June 26, Amoy Diagnostics announced that it has signed a companion diagnostic collaboration agreement with LES LABORATOIRES SERVIER (hereinafter referred to as 'Servier'). The company's independently developed second-generation sequencing (NGS) platform companion diagnostic product is used to detect mutations in the isocitrate dehydrogenase (IDH) 1 and 2 genes, and this companion diagnostic product will be used for Servier's investigational drug vorasidenib, which is a double inhibitor of mutated IDH1 and IDH2. It is expected to be used to treat Chinese patients with diffuse glioma (LGG) carrying IDH mutations after approval.
艾德生物：与施维雅签署伴随诊断合作协议
Amoy Diagnostics: Signed a Companion Diagnostic Collaboration Agreement with Roche.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.